Tajbakhsh Amir, Hosseinpour-Soleimani Fatemeh, Abedi Mehdi, Hashempur Mohammad Hashem, Negahdaripour Manica
Pharmaceutical Sciences Research Center (A.T., M.A., M.N.), Shiraz University of Medical Sciences, Iran.
Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies (A.T.), Shiraz University of Medical Sciences, Iran.
Stroke. 2025 Apr;56(4):1092-1103. doi: 10.1161/STROKEAHA.124.049048. Epub 2025 Mar 7.
Neuroinflammation significantly contributes to stroke pathophysiology, leading to tissue damage and neurological deficits. Baicalein, a potent 12/15-LOX (12/15-lipoxygenase) inhibitor, demonstrates neuroprotective effects by reducing inflammatory lipid mediators, modulating key inflammatory pathways, and attenuating oxidative stress. Experimental studies indicate that baicalein can diminish infarct size and neurological deficits while improving safety and tolerability. Combination therapies with baicalein show promise in enhancing stroke outcomes. Overall, targeting 12/15-LOX and employing baicalein represents a promising approach to modulating neuroinflammation and improving recovery in stroke patients. This review highlights the therapeutic potential of inhibiting the 12/15-LOX pathway and utilizing the natural compound baicalein to mitigate poststroke neuroinflammation.
神经炎症在很大程度上促成了中风的病理生理过程,导致组织损伤和神经功能缺损。黄芩素是一种有效的12/15-脂氧合酶(12/15-LOX)抑制剂,通过减少炎症脂质介质、调节关键炎症途径和减轻氧化应激来发挥神经保护作用。实验研究表明,黄芩素可以减小梗死灶大小并减轻神经功能缺损,同时提高安全性和耐受性。黄芩素联合疗法在改善中风预后方面显示出前景。总体而言,靶向12/15-LOX并使用黄芩素是调节神经炎症和改善中风患者恢复的一种有前景的方法。本综述强调了抑制12/15-LOX途径以及利用天然化合物黄芩素来减轻中风后神经炎症的治疗潜力。